NASDAQ:PALI Palisade Bio Q1 2025 Earnings Report $2.13 +0.06 (+2.90%) Closing price 08/26/2026 04:00 PM EasternExtended Trading$2.13 0.00 (0.00%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Palisade Bio EPS ResultsActual EPS-$0.47Consensus EPS -$0.84Beat/MissBeat by +$0.37One Year Ago EPSN/APalisade Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APalisade Bio Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateSunday, May 11, 2025Conference Call Time6:00PM ETUpcoming EarningsPalisade Bio's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Palisade Bio Earnings HeadlinesQ3 EPS Estimates for Palisade Bio Cut by AnalystAugust 20, 2026 | americanbankingnews.comPalisade Bio, Inc. (NASDAQ:PALI) Receives $9.00 Consensus PT from AnalystsAugust 19, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)FY2030 EPS Estimate for Palisade Bio Decreased by AnalystAugust 17, 2026 | americanbankingnews.comPalisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentAugust 11, 2026 | finanznachrichten.deAnalysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)August 11, 2026 | theglobeandmail.comSee More Palisade Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email. Email Address About Palisade BioPalisade Bio (NASDAQ:PALI) is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations. Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events. View Palisade Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaisePhotronics Is Quietly Becoming a Key Winner From the AI BoomOpenAI’s Jalapeño Chip Could Change the AI Hardware RaceHONA: The Spin-Off Story the Market Is Reading WrongPDD Beat Earnings—So Why Did the Stock Still Fall?Marzetti Stock Confirms Reversal on Earnings Strength, Dividend GrowthDICK's Sporting Goods Faces Pain Now for a Bigger Prize Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
